<DOC>
	<DOCNO>NCT01859234</DOCNO>
	<brief_summary>The purpose study see whether 89Zr-bevacizumab PET scan feasible relapse multiple myeloma patient .</brief_summary>
	<brief_title>89Zr-bevacizumab PET Scan Patients With Relapsing Multiple Myeloma</brief_title>
	<detailed_description>Multiple Myeloma ( MM ) clonal B cell disorder characterise monoclonal plasma cell population bone marrow , bone pain , anaemia , hypercalcaemia , kidney dysfunction clinically present symptom . Osseous involvement one predominant feature patient MM ; 90 % patient develop lytic bone lesion . Lytic bone lesion result increase bone resorption reduce bone formation . The regular method detect bone lesion skeletal survey . This technique detect lesion lose 30 % trabecular bone . Another weakness fact lesion persist treatment chemotherapy radiotherapy clear distinction make whether vital tumour cell persist lesion . New bone lesion sign disease progression . Furthermore give clinical sign bone pain bad case scenario pathological fracture . Alternative scan method develop visualize malignant plasma example making use enhance metabolic activity plasma cell define uptake 18F-fluorodeoxyglucose -Positron Emission tomography ( FDG-PET . The use FDG-PET newly diagnose MM patient well study . The increased FDG-uptake tumour relate high metabolic activity . This might consequence tumour hypoxia cause new vessel formation . There seem relationship MM angiogenesis , formation new blood vessel excite blood vessel . There increased microvessel density ( MVD ) affect bone marrow patient active MM . Vascular endothelial growth factor ( VEGF ) important mediator angiogenesis . MM cell line find express VEGF mRNA secrete protein extracellular environment thereby stimulate angiogenesis . Inhibition process angiogenesis use treatment MM , instance mean thalidomide lenalidomide . Blocking VEGF obtain mean bevacizumab , recombinant , humanise monoclonal antibody bind isoforms human VEGF high affinity . Treatment bevacizumab well establish solid tumour , like colon cancer renal cell carcinoma currently test acute myeloid leukaemia MM . VEGF image radiolabeled bevacizumab developed . Bevacizumab bind VEGF label PET isotope Zirconium-89 ( 89Zr ) preserve VEGF binding property . In human ovarian tumor xenograft , PET image 24 hour injection 89Zr-bevacizumab show high uptake well perfused organ tumor . The high VEGF production myeloma cell make VEGF interest target tumor visualization . 89Zr-bevacizumab PET imaging could sensitive myeloma lesion . So , conclusion , VEGF express MM plasma cell , thereby provide rationale assessment VEGF-levels micro-environment MM tumor could potentially use diagnostic tool see disease activity . Especially relapsed set invaluable importance , since conventional skeletal survey limitation set . Furthermore , 89Zr-bevacizumab PET imaging could provide information treatment option treatment response .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients relapse multiple myeloma accord international define guideline : Relapse achieve complete remission : 1 . Reappearance paraprotein 2 . More 5 % plasma cell bone marrow . 3 . New lytic lesion progression old lesion . 4 . New hypercalcaeamia . Relapse achieve partial remission 1 . Increases paraprotein 25 % 2 . Increase urine paraprotein 25 % 3 . Increase plasma cell bone marrow 10 % 4 . New lytic lesion progression old lesion 5 . New hypercalcaemia Radiotherapy last 3 month . Ineligible lay supine PET scan . Age ≤18 year . Pregnancy . Claustrophobia Severe kidney dysfunction ; serumcreatinine ≥250 µM</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>PET scan</keyword>
</DOC>